Hematologic Malignancy
Myelodysplastic/Myeloproliferative Neoplasm
CI-CAN-00001250Explore in graph →
Hematologic115 active trials3 approved drugs6 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001250Explore in graph →
Clinical trials
528 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (77)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00089037 | Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation | completed | Phase 1 / Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 15, 2011 | clinicaltrials |
| NCT00062140 | Total-Body Irradiation, Cyclophosphamide, and Stem Cell Transplantation in Treating Patients With Hematologic Cancer | completed | Phase 1 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 21, 2010 |
| clinicaltrials |
| NCT00049634 | Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Disorder | completed | Phase 1 / Phase 2 | 30 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 16, 2010 | clinicaltrials |
| NCT00054340 | Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder | completed | Phase 1 / Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | May 14, 2010 | clinicaltrials |
| NCT00293410 | Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders | completed | Phase 1 | 70 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 6, 2010 | clinicaltrials |
| NCT00255710 | Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer | completed | Phase 1 | 60 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 17, 2010 | clinicaltrials |
| NCT00003243 | Combination Chemotherapy Plus Infusion of White Blood Cells in Treating Patients With Hematologic Cancer | completed | Phase 1 | — | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 10, 2010 | clinicaltrials |
| NCT00004871 | Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | — | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 10, 2010 | clinicaltrials |
| NCT00006042 | Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer | completed | Phase 1 | — | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 10, 2010 | clinicaltrials |
| NCT00015925 | MS-275 in Treating Patients With Hematologic Cancer | completed | Phase 1 | — | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 10, 2010 | clinicaltrials |
| NCT00077558 | 3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome | completed | Phase 1 | — | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 10, 2010 | clinicaltrials |
| NCT00004058 | 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder | terminated | Phase 1 | — | University of Medicine and Dentistry of New JerseyOTHER | 1 | Jan 26, 2010 | clinicaltrials |
Data updated 22 days agoSource updated Jul 15, 2011source: clinicaltrials